Jia et al. [134] developed a PEGylated liposome with DOX, coupled to a high-affinity EGFR-antagonist affibody (ZEGFR), named AS-DOX, to target A431 tumor cells overexpressing EGFR and compared to non-targeted liposomes loaded with the drug (Figure 9). This evidence concerns the gene EGFR and neoplasm.